1. 50+ years' experience
Sterling’s experience enables us to maximise opportunities for our customers, whether they are small molecule, ADC or peptide development and manufacturing projects.
2. More than a traditional CDMO
In 2020, we redefined ourselves as a PDMO®*, because projects are always about more than molecules or simply a contract. Collaboration is key to creating lasting impact, together.
* Partnership development and manufacturing organisation
3. Global capacity across the US, EU and UK
Our Western-based development and manufacturing facilities are strategically located to support customers’ primary, secondary and dual supply strategies.
4. Experts in complex and hazardous projects
From controlled substances to HPAPIs, our network of experts work as an extension of customers’ teams; adapting as the project evolves, solving problems shoulder-to-shoulder.
5. An exceptional regulatory track record
We are extremely proud of our regulatory record, with successful audits across our global facilities from bodies including the MHRA, FDA, EMA, PDMA, HPRA and more.
It’s always about more than molecules.
